AI Maverick Intel Issues 76.5 Million Shares to HEAL Group Holdings Under ROFR Agreement

Rhea-AI Summary

AI Maverick Intel (AIMV) issued 76,500,000 common shares to HEAL Group Holdings as the initial tranche under a Right of First Refusal Agreement effective February 11, 2026. The total ROFR consideration shares were adjusted to 100,000,000 for AIMV’s planned acquisition of HEAL Access Canada. AIMV also plans to seek an OTCQB Venture Market uplisting as part of its capital markets strategy.

AI-generated analysis. Not financial advice.

Positive

• Initial 76.5M-share issuance advances HEAL Access Canada acquisition process
• Total ROFR consideration shares reduced from 120M to 100M
• ROFR Agreement supports 100% acquisition of HEAL Access Canada
• Company plans OTCQB Venture Market uplisting as part of capital strategy

Negative

• Issuance of 76.5M new shares increases AIMV share count and potential dilution
• Completion of HEAL Access Canada acquisition still subject to definitive agreement and conditions

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NEW YORK CITY, NY / ACCESS Newswire / May 12, 2026 / AI Maverick Intel, Inc. ("AIMV" or the "Company") today announced the issuance of 76,500,000 common shares to HEAL Group Holdings Inc. ("HEAL"), representing an initial tranche of the consideration shares issuable pursuant to the Right of First Refusal Agreement between the parties effective February 11, 2026 (the "ROFR Agreement").

As previously disclosed, AIMV has also exercised its right under the ROFR Agreement to acquire 100% of the issued and outstanding shares of HEAL Access Canada Inc., and the parties are proceeding toward execution of a definitive agreement. In connection with that proposed transaction, the total ROFR consideration shares have been adjusted from 120,000,000 to 100,000,000 common shares of AIMV, of which today's issuance represents the initial tranche.

"The issuance of these shares reflects our continued execution on the strategic framework established with HEAL Group," said Wayne Cockburn, Chief Executive Officer of AIMV. "We remain focused on completing the acquisition of HEAL Access Canada and advancing our position within the HEAL ecosystem."

AIMV also intends to pursue an uplisting of its common shares to the OTCQB Venture Market, subject to meeting applicable eligibility requirements, as part of its broader capital markets and financing strategy.

About AI Maverick Intel, Inc.

AI Maverick Intel, Inc. is focused on identifying and developing opportunities at the intersection of healthcare, data platforms and artificial intelligence. The Company evaluates strategic acquisitions, partnerships, and technology platforms designed to create scalable growth opportunities and long-term shareholder value.

About HEAL Group Holdings Inc.

HEAL Group Holdings Inc. is a privately held health technology and wellness platform company focused on building an integrated, data-driven ecosystem spanning healthcare services, digital health technology, through its AI division known as HEAL Access, with licensed Schedule 1 pharmaceutical distribution, and consumer wellness solutions. Backed by approximately US$75 million of family office capital invested over the past four years, HEAL has assembled a portfolio of approximately 25 entities and operating platforms across North America and Europe.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of applicable securities laws, including statements with respect to the proposed acquisition of HEAL Access Canada Inc., the intention and timing of entering into a definitive agreement, the completion thereof, the anticipated consideration and structure, and the satisfaction of minimum working capital requirements. Forward-looking statements involve risks and uncertainties that may cause actual results to differ materially from those expressed or implied. There can be no assurance that such statements will prove to be accurate. AIMV disclaims any intention or obligation to update forward-looking statements except as required by applicable law.

Stay Connected

Website: www.aimaverickintel.com
OTC:AIMV
X: @AIMaverickIntel

Media Contact

Wayne Cockburn, CEO
(905) 505-0770
Email: aimaverickintel@gmail.com

SOURCE: AI Maverick Intel, Inc.

View the original press release on ACCESS Newswire

FAQ

What did AI Maverick Intel (AIMV) announce about issuing 76.5 million shares on May 12, 2026?

AI Maverick Intel announced issuing 76,500,000 common shares to HEAL Group Holdings as an initial consideration tranche. According to the company, this issuance is under a Right of First Refusal Agreement tied to acquiring HEAL Access Canada and broader collaboration within the HEAL ecosystem.

How many ROFR consideration shares will AIMV issue for the HEAL Access Canada acquisition?

AIMV’s total Right of First Refusal consideration shares were adjusted to 100,000,000 common shares. According to the company, today’s 76,500,000-share issuance represents the initial tranche toward acquiring 100% of HEAL Access Canada, with remaining shares expected upon completion of a definitive agreement.

What is the ROFR Agreement between AI Maverick Intel (AIMV) and HEAL Group Holdings?

The ROFR Agreement, effective February 11, 2026, governs AIMV’s share-based consideration and acquisition rights with HEAL. According to the company, it enables AIMV to acquire 100% of HEAL Access Canada and structure up to 100,000,000 AIMV common shares as consideration to HEAL.

How does the HEAL Access Canada acquisition fit AI Maverick Intel’s (AIMV) strategy?

The HEAL Access Canada acquisition is described as central to AIMV’s strategic framework with HEAL Group. According to the company, acquiring 100% of HEAL Access Canada should deepen AIMV’s role in the HEAL ecosystem and support its broader capital markets and growth strategy.

What does AI Maverick Intel’s planned OTCQB uplisting mean for AIMV shareholders?

AIMV intends to pursue an uplisting of its common shares to the OTCQB Venture Market. According to the company, this planned step forms part of a broader capital markets and financing strategy and will depend on meeting all applicable OTCQB eligibility requirements.

When did the AI Maverick Intel (AIMV) and HEAL Group ROFR Agreement become effective?

The Right of First Refusal Agreement between AIMV and HEAL Group became effective on February 11, 2026. According to the company, this agreement underpins AIMV’s right to acquire 100% of HEAL Access Canada and governs the issuance of up to 100,000,000 AIMV consideration shares.